MRCP UK EXAMINATIONS

Detailed explanation-1: -Currently, intravenous tPA is the only widely available therapy for acute ischemic stroke that has proved to be beneficial. This therapy is effective for reducing neurological disability in selected patients who can be treated within 3 hours of stroke onset.

Detailed explanation-2: -FDA approves tPA for the treatment of acute ischemic stroke.

Detailed explanation-3: -Alteplase (tPA) intravenous thrombolysis is an effective treatment for acute ischemic stroke (AIS) when administered within 4.5 h of initial stroke symptoms. Here, its safety and efficacy were evaluated among AIS patients with a previous history of cerebral hemorrhage.

Detailed explanation-4: -There are strict protocols concerning the appropriate administration of tPA in patients with ischemic stroke, including a list of absolute and relative contraindications. Because of the risk of hemorrhage is thought to outweigh any potential benefits, patients with any absolute contraindication should not be given tPA.

Detailed explanation-5: -Who are ideal candidates for a tPA? There are two types of strokes-a stroke caused by a blockage and a stroke caused by bleeding. Blockages occur when an artery is blocked and the brain starts to die because of a lack of oxygen. A bleeding-type stroke is when a blood vessel has broken open inside the brain.